The value of serum prostate specific antigen and other parameters in detecting bone metastases in prostate cancer

International Urology and Nephrology

Volumn 31, Issue 4, 1999, Pages 481-489

  Ataus, S ^a   Citci A ^a   Alici, B ^a   Onder A U ^a   Sonmezoglu K ^a   Erozenci A ^a   Solok, V ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER GRADING; DIAGNOSTIC VALUE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE BIOPSY; PROSTATE CANCER;

BIOPSY; BONE NEOPLASMS; FALSE NEGATIVE REACTIONS; HUMANS; MALE; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0033403067     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007163227968     Document Type: Article

References (26)

1. Parker, S. L., Tong, T., Bolden, S., Wingo, P. A.: Cancer statistics, 1996. CA, 46, 5 (1996).
2. Oesterling, J. E.: Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol., 145, 907 (1991).
3. Benson, C. M., Olsson, C. A.: Prostate specific antigen and prostate specific antigen density. Cancer, 74, 6, 1667 (1994).
4. Ernst, D. S., Hanson, J., Venner, P. M., Uro-Oncology group of Northern Alberta: Analysis of prognostic factors in men with metastatic prostate cancer. J. Urol., 146, 372 (1991).
5. Cheryl, T. L., Oesterling, J. E.: Using prostate-specific antigen to eliminate the staging radionuclide bone scan. Urol. Clin. North Amer., 24 (2), 389 (1997).
6. Jacobs, S. C.: Spread of prostatic cancer to bone. Urology, 21, 337 (1983).
7. Paulson, D. F.: The impact of current staging procedures in assessing the disease extent of prostatic adenocarcinoma. J Urol., 121, 300 (1979).
8. McGregor, B., Tulloch, A. G. S., Quinlan, M. F., Lovegrove, F.: The role of bone scanning in the assessment of prostatic carcinoma. Br. J. Urol., 50, 178 (1978).
9. Lentle, B. C., McGowan, D. G., Dierich, H.: Technetium 99M polyphosphate bone scanning in carcinoma of the prostate. Br. J. Urol., 46, 543 (1974).
10. Pollen, J. J.: Bone scanning in prostatic cancer. Urology, 17, 31 (1981).
11. Parbhoo, S.: Serial scintiscans in monitoring patients with bone metastases. In: Stoll, B. A., Parbhoo, S. (eds): Bone Metastasis: Monitoring and Treatment. New York: Raven Press, 1983, p. 201.
12. Soloway, M. S., Hardeman, S. W., Hickey, D.: Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer, 61, 195 (1988).
13. Ohori, M., Wheeler, T. M., Scardino, P. T.: The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostatic cancer. Cancer, 74, 1 (1994).
14. Mellinger, G. T., Gleason, D., Bailar, J.: The histology and prognosis of prostatic cancer. J. Urol., 97, 331 (1967).
15. Stamey, T. A., McNeal, J. E.: Adenocarcinoma of the prostate. In: Walsh, P. C., Retik, A. B., Stamey, T. A., Vaughan, E. D. (eds): Campbell's Urology. Vol. 2, 6th Edit., W. B. Saunders Company, Philadelphia, 1992.
16. Merrick, M. V.: Bone scanning. Review article. Br. J Radiol., 48, 327 (1975).
17. Schaffer, D. L., Pendergrass, H. P.: Comparison of enzyme, clinical radiographic, and radionuclide methods of detecting bone metastases from carcinoma of the prostate. Radiology, 121, 431 (1976).
18. Maeda, H., Koizumi, M., Yoshimura, K., Yamauchi, T., Kawai, T., Ogata, E.: Correlation between bone metabolic markers and bone scan in prostatic cancer. J Urol., 157, 539 (1997).
19. McCarthy, P., Pollack, H. M.: Imaging of patients with stage D prostatic carcinoma. Urol. Clin North Am., 18, 35 (1991).
20. Andriole, G. L., Catalona, W. J.: Using PSA to screen for prostate cancer. The Washington University experience. Urol. Clin. North Am., 20, 647 (1993).
21. Haukaas, S., Roervik, J., Halvorsen, O. J., Foelling, M.: When is bone scintigraphy necessary in the assessment of newly diagnosed, untreated prostate cancer? Br. J. Urol., 79, 770 (1997).
22. Gleave, M. E., Coupland, D., Drachenberg, D., Cohen, L., Kwong, S., Goldenberg, S. L., Sullivan, L. D.: Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer. Urology, 47, 708 (1996).
23. Chybowski, F. M., Keller, J. J. L., Bergstrahl, E. J., Oesterling, J. E.: Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J. Urol., 145, 313 (1991).
24. Oesterling, J. E., Martin, S. K., Bergstrahl, E. J., Lowe, F. C.: The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. J.A.M.A., 269, 57 (1993).
25. Levran, Z., Gonzalez, J. A., Diokno, A. C., Jafri, S. Z. H., Steinert, B. W.: Are pelvic computed tomography, bone scan and pelvic lymphadenectomy necessary in the staging of prostatic cancer? Br. J. Urol., 75, 778 (1995).
26. Rees, M. A., McHugh, T. A., Dorr, R. P., Solomon, M. H., Lee, F., Littrup, P., Ann Arbor, M. I., Gonzalez, J. A., Levran, Z., Oak, R. M. I.: Assessment of the utility of bone scan, CT scan, and lymph node dissection in staging of patients with newly diagnosed prostate cancer. Proceedings of the American Urological Association, 153, 495, 1995S, 352A.